secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2026-05-12T12:15:16+00:00
Accession:  0001193125-26-218250
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Q1 net loss $23M, cash $138.2M; FDA alignment for CRB-701 registration path
--------------------------------------------------------------------------------

- Net loss of $23.0M ($1.23 diluted LPS) vs $17.0M loss ($1.39 LPS) in Q1 2025.
- Cash and investments $138.2M as of March 31, 2026, expected to fund operations into 2028.
- Reached broad FDA alignment on registration path for CRB-701 in 2L HNSCC and cervical cancer; registrational study start expected summer 2026.
- Updated CRB-701 data to be presented at ASCO 2026; CANYON-1 obesity study (n=240) fully enrolled, topline data summer 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526218250/0001193125-26-218250-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526218250/crbp-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-218250

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer